This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bard Announces First Quarter Results

C. R. Bard, Inc. (NYSE: BCR) today reported 2012 first quarter financial results. First quarter 2012 net sales were $730.0 million, an increase of 4 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2012 net sales increased 5 percent over the prior-year period.

For the first quarter 2012, net sales in the U.S. were $496.2 million, an increase of 2 percent over the prior-year period. Net sales outside the U.S. were $233.8 million, an increase of 10 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2012 net sales outside the U.S. increased 11 percent over the prior-year period.

For the first quarter 2012, net income was $138.7 million and diluted earnings per share available to common shareholders were $1.60, an increase of 5 percent and 7 percent, respectively, as compared to first quarter 2011 results. Adjusting for items that affect comparability between periods as detailed in the tables below, first quarter 2012 net income was $139.5 million and diluted earnings per share available to common shareholders were $1.61, an increase of 4 percent and 7 percent, respectively, as compared to first quarter 2011 results.

Timothy M. Ring, chairman and chief executive officer, commented, “The results this quarter reflect a good start to the year. While we haven’t seen much change in the U.S. environment, our increased focus and investments in international markets have provided rapid returns and strengthened our growth profile. We remain focused on daily execution of our product leadership strategy to take advantage of current opportunities while positioning ourselves for stronger growth in the future.”

C. R. Bard, Inc. ( www.crbard.com ), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our December 31, 2011 Form 10-K for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.
C. R. Bard, Inc.
Consolidated Statements of Income
(dollars and shares in thousands except per share amounts, unaudited)
         
Quarter Ended
March 31,

2012

2011
 
Net sales $ 730,000 $ 700,300
Costs and expenses
Cost of goods sold 279,400 264,800
Marketing, selling and administrative expense 202,300 194,300
Research and development expense 48,200 48,000
Interest expense 9,500 9,100
Other (income) expense, net   (800 )   100
 
Total costs and expenses   538,600     516,300
Income from operations before income taxes   191,400     184,000
 
Income tax provision   52,700     52,100
Net income $ 138,700   $ 131,900
 
Basic earnings per share available to common shareholders $ 1.62   $ 1.52
 
Diluted earnings per share available to common shareholders $ 1.60   $ 1.49
 
Wt. avg. common shares outstanding - basic 84,100 85,300
 
Wt. avg. common and common equivalent shares outstanding - diluted 85,100 87,000
 
 
Product Group Summary of Net Sales
(dollars in thousands, unaudited)
           
 
Quarter Ended March 31,
Constant
2012   2011     Change   Currency
Vascular $ 209,200 $ 198,300 5 % 6 %
Urology 185,100 179,500 3 % 3 %
Oncology 198,900 186,400 7 % 7 %
Surgical Specialties 114,700 114,900 - -
Other   22,100   21,200   4 % 5 %
 
Net sales $ 730,000 $ 700,300   4 %
 
Foreign exchange impact     (2,300 )
Constant Currency $ 730,000 $ 698,000   5 %
 
 
Reconciliation of Earnings
(dollars in millions except per share amounts, unaudited)
                           
 
Quarter Ended March 31, 2012
Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net   Taxes Income Shareholders
 
GAAP Basis $ 279.4 $ 202.3 $ 48.2 $ (0.8 ) $ 52.7 $ 138.7 $ 1.60

Items that affect comparability of results between periods:
 
Acquisition related items - - (0.4 ) (0.6 ) 0.2 0.8 0.01
             
Adjusted Basis $ 279.4 $ 202.3   $ 47.8   $ (1.4 ) $ 52.9 $ 139.5 $ 1.61
 
 
Quarter Ended March 31, 2011
Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net   Taxes Income Shareholders
 
GAAP Basis $ 264.8 $ 194.3 $ 48.0 $ 0.1 $ 52.1 $ 131.9 $ 1.49

Items that affect comparability of results between periods:
 
Acquisition related items 0.6 (0.2 ) (3.0 ) (0.2 ) 1.0 1.8 0.02
             
Adjusted Basis $ 265.4 $ 194.1   $ 45.0   $ (0.1 ) $ 53.1 $ 133.7 $ 1.51
 
 

Notes to Reconciliation of Earnings
  • For the three months ended March 31, 2012, a charge of $1.0 million pre-tax for acquisition-related items including transaction costs, purchase accounting adjustments and integration costs, affected the comparability of results between periods. The effect of this charge decreased net income by $0.8 million, or $0.01 diluted earnings per share available to common shareholders.
  • For the three months ended March 31, 2011, a charge of $2.8 million pre-tax for acquisition-related items including purchased research and development, transaction costs, purchase accounting adjustments and integration costs, affected the comparability of results between periods. The effect of this charge decreased net income by $1.8 million, or $0.02 diluted earnings per share available to common shareholders.

This press release contains financial measures that are not calculated in accordance with United States generally accepted accounting principles (GAAP). These non-GAAP measures are reconciled to their most directly comparable GAAP measures in the above tables.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs